Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William D. Waddill Sells 8,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William D. Waddill sold 8,000 shares of the stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $40.00, for a total value of $320,000.00. Following the transaction, the director now owns 12,000 shares in the company, valued at approximately $480,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Protagonist Therapeutics Stock Performance

Shares of PTGX opened at $40.28 on Monday. Protagonist Therapeutics, Inc. has a 52-week low of $13.72 and a 52-week high of $42.67. The business’s fifty day moving average is $33.64 and its 200-day moving average is $29.67. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of 16.51 and a beta of 2.13.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $3.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.75. The business had revenue of $254.95 million during the quarter, compared to the consensus estimate of $300.00 million. As a group, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. bought a new position in shares of Protagonist Therapeutics in the 1st quarter valued at $35,000. Lazard Asset Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 1st quarter valued at $69,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Protagonist Therapeutics by 353.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,675 shares of the company’s stock valued at $153,000 after acquiring an additional 5,202 shares in the last quarter. Seven Eight Capital LP acquired a new stake in shares of Protagonist Therapeutics during the 1st quarter valued at $202,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at $210,000. Institutional investors own 98.63% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. JMP Securities reiterated a “market outperform” rating and set a $45.00 target price on shares of Protagonist Therapeutics in a research note on Monday, June 17th. JPMorgan Chase & Co. raised their price objective on Protagonist Therapeutics from $39.00 to $48.00 and gave the stock an “overweight” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, June 14th. Finally, BTIG Research raised their price objective on Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $42.80.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.